JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

Overview

This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.

Full Title of Study: “A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Sequential Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 2024

Detailed Description

The primary objective of this study is to evaluate the safety and tolerability of JAB-2485 monotherapy to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) during Dose Escalation phase when administered in participants with advanced solid tumors; then to further evaluate preliminary antitumor activity of JAB-2485 monotherapy at the RP2D during Dose Expansion phase in patients with advanced solid tumors such as ER+ breast cancer, triple negative breast cancer (TNBC), AT-rich interaction domain 1A (ARID1A) mutant solid tumors and small cell lung cancer (SCLC).

Interventions

  • Drug: JAB-2485 (Aurora A inhibitor)
    • Administered orally
  • Drug: JAB-2485 (Aurora A inhibitor)
    • Administered orally

Arms, Groups and Cohorts

  • Experimental: JAB-2485 monotherapy, Phase 1, Dose Escalation
    • Dose escalation of JAB-2485 will be administered as monotherapy to determine the MTD and RP2D.
  • Experimental: JAB-2485 monotherapy, Phase 2a, Dose Expansion
    • JAB-2485 will be administered as monotherapy in patients with specific tumor types to evaluate the preliminary antitumor activity.

Clinical Trial Outcome Measures

Primary Measures

  • Dose Escalation phase: Number of participants with dose limiting toxicities (DLTs)
    • Time Frame: First 21 days of Cycle 1
    • A DLT is defined as an adverse event (AE) regardless of attribution unless clearly related to underlying disease or extraneous cause during the first 21 days of Cycle 1 (DLT observation period).
  • Dose Escalation phase: Number of participants with adverse events (AEs)
    • Time Frame: Up to 3 years
    • Participants will be assessed for incidence and severity of AEs according to NCI-CTCAE v5.0
  • Dose Expansion phase: Objective Response Rate (ORR)
    • Time Frame: Up to 3 years from baseline to RECIST confirmed Progressive Disease (PD)
    • ORR is defined as the percentage of participants with partial response (PR) or complete response (CR) based on RECIST v1.1
  • Dose Expansion phase: Duration of Response (DOR)
    • Time Frame: Up to 3 years
    • DOR is defined as the time from the participants initial objective response (CR or PR) to disease progression per CTCAE v1.1 or death due to any cause, whichever occurs first.

Secondary Measures

  • Dose Escalation phase: Objective Response Rate (ORR)
    • Time Frame: Up to 3 years from baseline to RECIST confirmed Progressive Disease (PD)
    • ORR is defined as the percentage of participants with PR or CR based on RECIST v1.1
  • Dose Escalation and Dose Expansion phase: Time to response (TTR)
    • Time Frame: Up to 3 years
    • TTR is defined as the interval of time between the date of first treatment to the first documented response (CR or PR) as determined by investigator assessment per RECIST v1.1
  • Dose Escalation phase: Duration of Response (DOR)
    • Time Frame: Up to 3 years
    • DOR is defined as the time from the participants initial objective response (CR or PR) to disease progression per CTCAE v1.1 or death due to any cause, whichever occurs first
  • Dose Escalation and Dose Expansion phase: peak plasma concentration (Cmax)
    • Time Frame: Up to 3 years
    • Pharmacokinetic (PK) parameters of JAB-2485 monotherapy and the food effect assessment by using plasma or urine PK samples, including peak plasma concentration (Cmax)
  • Dose Escalation and Dose Expansion phase: time to peak plasma concentration(Tmax)
    • Time Frame: Up to 3 years
    • Pharmacokinetic (PK) parameters of JAB-2485 monotherapy and the food effect assessment by using plasma or urine PK samples. Including time to peak plasma concentration (tmax)
  • Dose Escalation and Dose Expansion phase: Ctrough
    • Time Frame: Up to 3 years
    • Pharmacokinetic (PK) parameters of JAB-2485 monotherapy and the food effect assessment by using plasma or urine PK samples. Including pre-dose through concentration (Ctrough)
  • Dose Escalation and Dose Expansion phase: Area under the curve (AUC)
    • Time Frame: Up to 3 years
    • Pharmacokinetic (PK) parameters of JAB-2485 monotherapy and the food effect assessment by using plasma or urine PK samples. Including area under the plasma concentration versus time curve (AUC)
  • Dose Escalation and Dose Expansion phase: half-life (t½)
    • Time Frame: Up to 3 years
    • Pharmacokinetic (PK) parameters of JAB-2485 monotherapy and the food effect assessment by using plasma or urine PK samples. Including half-life (t½)
  • Dose Escalation and Dose Expansion phase: total body clearance
    • Time Frame: Up to 3 years
    • Pharmacokinetic (PK) parameters of JAB-2485 monotherapy and the food effect assessment by using plasma or urine PK samples. Including total body clearance
  • Dose Expansion phase: Progression Free Survival (PFS)
    • Time Frame: Up to 3 years
    • PFS is defined as the interval of time between the date of first treatment to the earliest date of disease progression per RECIST v1.1 or death which occurs first.
  • Dose Expansion Phase 2a: Overall Survival (OS)
    • Time Frame: Up to 3 years
    • OS is defined as the length of time between the date of first treatment to the date of death
  • Dose Expansion phase: Disease Control Rate (DCR)
    • Time Frame: Up to 3 years
    • DCR is defined as percentage of participants with complete response (CR), partial response (PR), or stable disease (SD) per RECIST v1.1
  • Dose Expansion phase: Number of participants with adverse events (AEs)
    • Time Frame: Up to 3 years
    • Participants will be assessed for incidence and severity of AEs according to NCI-CTCAE v5.0

Participating in This Clinical Trial

Inclusion Criteria

  • Must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 – Must be able to provide an archived tumor sample – Must have histologically or cytologically confirmed metastatic or locally advanced solid tumor – Dose Expansion phase cohorts must meet specific expression or gene mutation where indicated – Must be refractory to or become intolerant of existing therapy(ies) known to provide clinical benefit for their condition – Must have at least 1 measurable lesion per RECIST v1.1 – Must have adequate organ functions – Must be able to swallow and retain orally administered medication Exclusion Criteria:

  • Has central nervous system (CNS) metastases or carcinomatous meningitis, except if CNS metastases treated and no evidence of radiographic progression or hemorrhage for at least 28 days – Active infection requiring systemic treatment within 7 days – Active hepatitis B virus (HBV), hepatitis C virus (HCV), or HIV – Any severe and/or uncontrolled medical conditions – left ventricular ejection fraction (LVEF) ≤50% assessed by echocardiogram (ECHO) or multigated acquisition scan (MUGA) – QT interval using Fridericia's formula (QTcF) interval >470 msec – Experiencing unresolved CTCAE 5.0 Grade >1 toxicities – Clinically significant eye disorders

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Jacobio Pharmaceuticals Co., Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jacobio Pharmaceuticals, Study Director, Jacobio Pharmaceuticals
  • Overall Contact(s)
    • Jacobio Pharmaceuticals, (781) 918-6670, clinicaltrials@jacobiopharma.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.